GTBP on Nasdaq

GT Biopharma, Inc.

American pharmaceutical preparations company based in San Francisco. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with AcelRx Pharmaceuticals (United States), Rafael Holdings, Inc. or IMPACT BIOMEDICAL INC., or pick any stock.

  • TickerGTBP on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Francisco, California1
  • Incorporated inDE2
  • Business address505 Montgomery Street, 10Th Floor, San Francisco, Ca 941112
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy, as agreed on with the FDA.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue4$0 in 2020
02019: $0$020192020: $0$02020
Operating income45-$6.8M in 2020
-$10.0M0$10.0M$20.0M2019: $16.1M$16.1M20192020: -$6.8M-$6.8M2020
Net income45-$28.3M in 2020−27% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$38.6M-$38.6M20192020: -$28.3M-$28.3M2020−27%

Every line of the income statement as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.8

Period ending2025-12-312024-12-31
Research and development$3.5M$5.8M
Selling, general and administrative (including $432,000 and $230,000 of stock compensation during the years ended December 31, 2025 and 2024, respectively)$8.9M$8.6M
Loss from Operations-$12.4M-$14.4M
Interest income$123.0K$402.0K
Interest expense-$127.0K
Loss on initial recognition of Greenshoe Rights liability-$28.7M
Change in fair value of Greenshoe Rights liability$11.4M
Change in fair value of warrant liability$241.0K$800.0K
Gain on settlement of vendor payable$998.0K
Other$156.0K
Total Other Income (Expense), Net-$15.9M$1.2M
Net Loss-$28.4M-$13.2M
Dividend on Series L Preferred Stock-$320.0K
Deemed dividend-$5.8M
Net Loss attributable to common stockholders-$34.4M-$13.2M
Net Loss Per Share - Basic-$6.68-$6.94
Net Loss Per Share - Diluted-$6.68-$6.94
Weighted average common shares outstanding - basic5.5M shares1.9M shares
Weighted average common shares outstanding - diluted5.5M shares1.9M shares

Compare GT Biopharma, Inc. with another company

Leadership

Who has led GT Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Marvin S. Hausman Md.2006–2008
  2. David Saloff2011–2012
  3. Kathleen Clarence-Smith2017
  4. Shawn Cross2018
  5. Raymond W. Urbanski2019
  6. Michael Martin Breen2022–now

Chair

  1. David Saloff2012
  2. Michael Martin Breen2022–2023

President

  1. Marvin S. Hausman Md.2006–2008
  2. Bernard Landes2010

Chief financial officer

  1. Michael D. Centron2006
  2. Michael D. Handelman2010
  3. Steven W. Weldon2016–2020
  4. Gavin Choy2022
  5. Manu Ohri2022–2023
  6. Alan Louis Urban2024–now

Chief operating officer

  1. Gary M. Post2007
2010201520202025
Board members and other officers (26)

Former names

  • OXIS INTERNATIONAL INCJun 8, 1995 to Jul 25, 20172

Timeline

  1. Jul 19, 2022New chief executive Michael Martin Breen becomes CEO11
  2. Mar 19, 2019New chief executive Raymond W. Urbanski becomes CEO12
  3. Mar 16, 2018New chief executive Shawn Cross becomes CEO13
  4. Dec 1, 2017New chief executive Kathleen Clarence-Smith becomes CEO14
  5. Sep 1, 2011New chief executive David Saloff becomes CEO15
  6. Oct 16, 2006New chief executive Marvin S. Hausman Md. becomes CEO16

Filings

200 filings to the SEC since October 2021: 6 annual reports, 18 quarterly reports, 53 major events, 38 insider forms, 11 large holders, 4 private raises, 70 other. The latest 20:

  1. Oct 13, 2026DEF 14A EDGAR
  2. Oct 9, 2026S-1 EDGAR
  3. Oct 2, 2026PRE 14A EDGAR
  4. Sep 29, 2026D EDGAR
  5. Sep 25, 20268-K EDGAR
  6. Sep 21, 20268-K EDGAR
  7. Sep 15, 20268-K EDGAR
  8. Sep 15, 2026SCHEDULE 13G EDGAR
  9. Sep 3, 20268-K EDGAR
  10. Aug 14, 20268-K EDGAR
  11. Aug 14, 202610-Q EDGAR
  12. Jul 2, 2026DEF 14A EDGAR
  13. Jun 18, 2026PRE 14A EDGAR
  14. Jun 12, 20268-K EDGAR
  15. May 22, 20268-K EDGAR
  16. May 15, 202610-Q EDGAR
  17. May 13, 2026EFFECT EDGAR
  18. May 13, 2026424B3 EDGAR
  19. May 11, 2026CORRESP EDGAR
  20. May 6, 2026UPLOAD EDGAR

The 200 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 11, 2023Breen Michael MartinCEO and DirectorBuy50,000$0.50$25.0KForm 4
Apr 6, 2023Ohri ManuCFO & SecretaryBuy50,000$0.50$25.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 14, 2026Raised $7.8 million in a private offering of equity Form D: $39 million offered in all Form D
  2. May 14, 2025Filed a private offering of equity Form D: $20 million offered in all Form D
  3. May 12, 2025Raised $6 million in a private offering of equity Form D: 9 investors so far Form D
  4. Feb 25, 2025Raised $1.3 million in a private offering of equity Form D: 6 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54